PF-562271, a small-molecule inhibitor of Pyk2 and FAK that was provided orally 2 days before a planned surgical tumor resection and continued throughout the post-surgical period significantly reduced tumor growth and increased the median survival of the animals by 33%, compared with non-treated controls. Here, PTK2B is linked to neoplasm.